AGN Media thread, page-133

Are you actually serious ? If/when we start a phase 2 for TBI etc, dosage rates and delivery methods below have been proven safe already. Do you expect we do another phase 1 that is 100% identical to the first phase 1 trial ?

The aim of this pilot study was to investigate whether ARG-007, delivered intravenously at
either a 100 nmol/kg or 300 nmol/kg dose, can improve motor and cognitive outcome with
an associated reduction in axonal injury and neuroinflammation at 3 days following a mildmoderate diffuse head injury in ferrets. The animals were randomly allocated via a random
number generator to sham (uninjured) (n = 9) or injury (n = 25), with injured ferrets
administered either vehicle (saline; n = 10), 100nmol/kg (0.3 mg/kg) R18D (n =8) or
300nmol/kg (0.9 mg/kg) R18D (n = 7).

I'm thinking you are trying to get some cheap shares with a bit of misinformation ... good luck